<DOC>
	<DOCNO>NCT02058693</DOCNO>
	<brief_summary>In Phase 4 trial study safety , tolerability efficacy mixed salt amphetamine ( MSA ) , trade name Adderall , augmentation antidepressant therapy Major Depressive Disorder ( MDD ) depress outpatient adult take antidepressant complete resolution symptom . 40 adult outpatient MDD fail least one adequate trial antidepressant monotherapy consent 63-day , cross-sequential , multicenter study comprise two treatment phase 21 day . The time frame consent baseline 7 day . Patients receive placebo MSA Phase 1 , Phase 2 , participant receive MSA . There also two-week follow visit completion Phase 2 . We hypothesize MSA safe well tolerate , improve patient 's response antidepressant provide superior symptom relief antidepressant alone . The primary outcome measure Massachusetts General Hospital Cognitive-Physical Function Questionnaire ( MGH-CPFQ ) .</brief_summary>
	<brief_title>Adjunctive Mixed Salts Amphetamine ( MSA ) Depressed Adults With Incomplete Response Current Antidepressant Therapy ( ADT )</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>1 . Male female outpatient age 1870 . 2 . Subject must meet criterion single recurrent , nonpsychotic episode MDD accord Diagnostic Statistical Manual IV Text Revised ( DSMIVTR ) diagnosis , determine Structured Clinical Inventory Depressive Symptoms ( SCID ) confirm assessment investigator . 3 . Current depressive episode must least 8 week duration . 4 . Hamilton Depression Rating Scale 17 ( HDRS17 ) score â‰¥ 14 screen baseline visit . 5 . Subject must receive adequate , stable dose ADT , base Massachusetts General HospitalAntidepressant Treatment Response Questionnaire ( MGHATRQ ) . 6 . Subject must respond inadequately his/her current monotherapy ADT current major depressive episode ( MDE ) . 7 . Subjects must able read understand English able provide write informed consent . 8 . Subjects must consider reliable , able comply protocol requirement understand risk benefit , per investigator 's clinical judgment . 9 . Female subject childbearing potential must agree use adequate form birth control throughout course study . 1 . Inadequate response current episode 3 adequate trial ADT , define MGHATRQ . 2 . Psychiatric hospitalization within last 6 month . 3 . Presence cognitive disorder ( ) , bipolar disorder , Axis II pathology condition investigator believe would interfere participation study . 4 . Substance use disorder , current ( defined DSMIVTR SCID ) positive result urine drug screen laboratory blood test . 5 . Risk self others . 6 . The presence medical condition , current past , stable unstable , contraindicates use antidepressant medication mixed amphetamine salt medication determine clinician 's judgment . 7 . Clinically significant abnormal finding physical exam , EKG laboratory test ; current unstable , untreated hypertension opinion investigator ; history cerebrovascular accident ( CVA ) seizure disorder ( febrile childhood seizure ) . 8 . Allergies and/or adverse drug reaction MSA . 9 . Failure respond adequate trial MSA adjunctive ADT current episode . 10 . Subjects take narcotic , herbal/homeopathic remedy and/or substance psychotropic activity , base upon clinical judgment study investigator . 11 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>